Research & Literature

Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011.

O'Grady TJ, Gates MA, Boscoe FP

International journal of cancer 2015; (137(11)):2664-73 doi:10.1002/ijc.29634.

Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.

Yip L, Nikiforova MN, Yoo JY, et al.

Annals of surgery 2015; (262(3)):519-25; discussion 524-5 doi:10.1097/SLA.0000000000001420.

Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology.

Pacini F, Brianzoni E, Durante C, et al.

Journal of endocrinological investigation 2016; (39(3)):341-7 doi:10.1007/s40618-015-0375-7.

Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.

Furtado Mde S, Rosario PW, Calsolari MR

Archives of endocrinology and metabolism 2015; (59(4)):285-91.

Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review.

Clement SC, Peeters RP, Ronckers CM, et al.

Cancer treatment reviews 2015; (41(10)):925-34.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Haugen BR, Alexander EK, Bible KC, et al.

Thyroid : official journal of the American Thyroid Association 2016; (26(1)):1-133 doi:10.1089/thy.2015.0020.

Iatrogenic myxoedema madness following radioactive iodine ablation for Graves' disease, with a concurrent diagnosis of primary hyperaldosteronism.

Larouche V, Snell L, Morris DV

Endocrinology, diabetes & metabolism case reports 2015; (2015()):150087 doi:10.1530/EDM-15-0087.

Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.

Teng CJ, Hu YW, Chen SC, et al.

Journal of the National Cancer Institute 2016; (108(2)).

[Advances in thyroglobulin assays and their impact on the management of differentiated thyroid cancers].

d'Herbomez M, Lion G, Béron A, et al.

Annales de biologie clinique 2016; (74(1)):21-7 doi:10.1684/abc.2015.1106.

Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.

Kim SK, Woo JW, Lee JH, et al.

Endocrine-related cancer 2016; (23(5)):367-76 doi:10.1530/ERC-15-0572.

Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Han PA, Kim HS, Cho S, et al.

Thyroid : official journal of the American Thyroid Association 2016; (26(4)):532-42 doi:10.1089/thy.2015.0378.

Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.

Momesso DP, Vaisman F, Yang SP, et al.

The Journal of clinical endocrinology and metabolism 2016; (101(7)):2692-700 doi:10.1210/jc.2015-4290.

A National Perspective of the Risk, Presentation, and Outcomes of Pediatric Thyroid Cancer.

Al-Qurayshi Z, Hauch A, Srivastav S, et al.

JAMA otolaryngology-- head & neck surgery 2016; (142(5)):472-8 doi:10.1001/jamaoto.2016.0104.

[Intracellular signaling mechanisms in thyroid cancer].

Mondragón-Terán P, López-Hernández LB, Gutiérrez-Salinas J, et al.

Cirugia y cirujanos 2016; (84(5)):434-43.

Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.

Liu R, Bishop J, Zhu G, et al.

JAMA oncology 2017; (3(2)):202-208 doi:10.1001/jamaoncol.2016.3288.

Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.

Rossi M, Lupo S, Rossi R, et al.

Endocrine 2017; (57(1)):98-107 doi:10.1007/s12020-016-1105-4.

Extent of Extrathyroidal Extension as a Significant Predictor of Nodal Metastasis and Extranodal Extension in Patients with Papillary Thyroid Carcinoma.

Kim JW, Roh JL, Gong G, et al.

Annals of surgical oncology 2017; (24(2)):460-468 doi:10.1245/s10434-016-5594-4.

Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.

Kim SK, Park I, Woo JW, et al.

Thyroid : official journal of the American Thyroid Association 2017; (27(2)):207-214 doi:10.1089/thy.2016.0190.

Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.

Moon S, Song YS, Kim YA, et al.

Thyroid : official journal of the American Thyroid Association 2017; (27(5)):651-660 doi:10.1089/thy.2016.0350.

Update on the cytologic features of papillary thyroid carcinoma variants.

Pusztaszeri M, Auger M

Diagnostic cytopathology 2017; (45(8)):714-730 doi:10.1002/dc.23703.

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: An Evidence-Based Nomenclature Change.

Jug R, Jiang X

Pathology research international 2017; (2017()):1057252 doi:10.1155/2017/1057252.

Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials.

Ito Y, Miyauchi A, Oda H

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2018; (44(3)):307-315 doi:10.1016/j.ejso.2017.03.004.

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Lim H, Devesa SS, Sosa JA, et al.

JAMA 2017; (317(13)):1338-1348 doi:10.1001/jama.2017.2719.

Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer.

de Meer SGA, Vorselaars WMCM, Kist JW, et al.

Endocrine research 2017; (42(4)):302-310 doi:10.1080/07435800.2017.1319858.

Patients with Multifocal Macroscopic Papillary Thyroid Carcinoma Have a Low Risk of Recurrence at Early Follow-Up after Total Thyroidectomy and Radioactive Iodine Treatment.

La Greca A, Xu B, Ghossein R, et al.

European thyroid journal 2017; (6(1)):31-39 doi:10.1159/000448752.

The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications.

Rodrigues AC, Penna G, Rodrigues E, et al.

Current genomics 2017; (18(3)):244-254 doi:10.2174/1389202918666170105094459.

Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

Xu B, Ghossein RA

Histopathology 2018; (72(1)):32-39 doi:10.1111/his.13335.

Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.

Andresen NS, Buatti JM, Tewfik HH, et al.

European thyroid journal 2017; (6(4)):187-196 doi:10.1159/000468927.

Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Perrier ND, Brierley JD, Tuttle RM

CA: a cancer journal for clinicians 2018; (68(1)):55-63 doi:10.3322/caac.21439.

High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.

Mazziotti G, Formenti AM, Frara S, et al.

The Journal of clinical endocrinology and metabolism 2018; (103(3)):956-964 doi:10.1210/jc.2017-01986.

Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.

Pajamäki N, Metso S, Hakala T, et al.

Clinical endocrinology 2018; (88(2)):303-310 doi:10.1111/cen.13519.

A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.

Jeon MJ, Kim M, Park S, et al.

Thyroid : official journal of the American Thyroid Association 2018; (28(2)):187-192 doi:10.1089/thy.2017.0130.

A user's guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Hung YP, Barletta JA

Histopathology 2018; (72(1)):53-69 doi:10.1111/his.13363.

High suspicion US pattern on the ATA guidelines, not cytologic diagnosis, may be a predicting marker of lymph node metastasis in patients with classical papillary thyroid carcinoma.

Cho E, Kim EK, Moon HJ, et al.

American journal of surgery 2018; (216(3)):562-566 doi:10.1016/j.amjsurg.2017.12.006.

Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence.

Hughes DT, Rosen JE, Evans DB, et al.

Annals of surgical oncology 2018; (25(9)):2526-2534 doi:10.1245/s10434-018-6528-0.

Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.

Schlumberger M, Leboulleux S, Catargi B, et al.

The lancet. Diabetes & endocrinology 2018; (6(8)):618-626 doi:10.1016/S2213-8587(18)30113-X.

Skull Metastasis Extending to the Superior Sagittal Sinus: An Unfamiliar Presentation of Papillary Thyroid Carcinoma.

Sheikh AB, Akhtar A, Tariq U, et al.

Cureus 2018; (10(6)):e2738 doi:10.7759/cureus.2738.

Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm.

Lee YM, Cho JW, Hong SJ, Yoon JH

Journal of surgical oncology 2018; (118(4)):636-643 doi:10.1002/jso.25182.

Thyroid Ultrasound and the Increase in Diagnosis of Low-Risk Thyroid Cancer.

Haymart MR, Banerjee M, Reyes-Gastelum D, et al.

The Journal of clinical endocrinology and metabolism 2019; (104(3)):785-792 doi:10.1210/jc.2018-01933.

The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Vita R, Ieni A, Tuccari G, Benvenga S

Reviews in endocrine & metabolic disorders 2018; (19(4)):301-309 doi:10.1007/s11154-018-9474-z.

The Current Histologic Classification of Thyroid Cancer.

Asa SL

Endocrinology and metabolism clinics of North America 2019; (48(1)):1-22 doi:10.1016/j.ecl.2018.10.001.

The relationships of surgeon volume and specialty with outcomes following pediatric thyroidectomy.

Drews JD, Cooper JN, Onwuka EA, et al.

Journal of pediatric surgery 2019; (54(6)):1226-1232 doi:10.1016/j.jpedsurg.2019.02.033.

Genomic Characterization of Differentiated Thyroid Carcinoma.

Song YS, Park YJ

Endocrinology and metabolism (Seoul, Korea) 2019; (34(1)):1-10 doi:10.3803/EnM.2019.34.1.1.

Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend.

Malandrino P, Tumino D, Russo M, et al.

Journal of endocrinological investigation 2019; (42(10)):1223-1230 doi:10.1007/s40618-019-01044-3.

Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.

Lee MC, Kim MJ, Choi HS, et al.

Endocrinology and metabolism (Seoul, Korea) 2019; (34(2)):150-157 doi:10.3803/EnM.2019.34.2.150.

SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.

Deng Y, Zhu G, Ouyang W, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(9)):887-898 doi:10.4158/EP-2018-0583.

Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy.

DiMarco AN, Wong MS, Jayasekara J, et al.

BJS open 2019; (3(3)):299-304 doi:10.1002/bjs5.50137.

Critical Prognostic Parameters in the Anatomic Pathology Reporting of Differentiated Follicular Cell-Derived Thyroid Carcinoma.

Xu B, Ghossein R

Cancers 2019; (11(8)) doi:10.3390/cancers11081100.

Prognostic Parameters in Differentiated Thyroid Carcinomas.

Cipriani NA

Surgical pathology clinics 2019; (12(4)):883-900 doi:10.1016/j.path.2019.07.001.

Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.

van Velsen EFS, Visser WE, van den Berg SAA, et al.

Thyroid : official journal of the American Thyroid Association 2020; (30(4)):580-587 doi:10.1089/thy.2019.0504.

Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?

Moreno I, Hirsch D, Duskin-Bitan H, et al.

Thyroid : official journal of the American Thyroid Association 2020; (30(6)):863-870 doi:10.1089/thy.2019.0431.

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity.

Zajkowska K, Kopczyński J, Góźdź S, Kowalska A

Endocrine connections 2020; (9(3)):R47-R58 doi:10.1530/EC-19-0566.

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.

Al-Salam S, Sharma C, Afandi B, et al.

PloS one 2020; (15(4)):e0231341 doi:10.1371/journal.pone.0231341.

Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.

Horvath E, Skoknic V, Majlis S, et al.

Thyroid : official journal of the American Thyroid Association 2020; (30(11)):1646-1655 doi:10.1089/thy.2019.0563.

Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.

Al Dawish M, Alwin Robert A, Al Shehri K, et al.

Cureus 2020; (12(5)):e8202 doi:10.7759/cureus.8202.

Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.

Kim Y, Roh JL, Song D, et al.

Journal of surgical oncology 2020; (122(5)):906-913 doi:10.1002/jso.26090.

The importance of risk of neoplasm as an outcome in cytologic-histologic correlation studies on thyroid fine needle aspiration.

Chen YH, Partyka KL, Dougherty R, et al.

Diagnostic cytopathology 2020; (48(12)):1237-1243 doi:10.1002/dc.24557.

Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis.

Lechner MG, Bernardo AC, Lampe A, et al.

The oncologist 2021; (26(2)):e251-e260 doi:10.1634/theoncologist.2020-0306.

Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting.

Ghossein R, Barletta JA, Bullock M, et al.

Human pathology 2021; (110()):62-72 doi:10.1016/j.humpath.2020.08.009.

Impact of Gross Strap Muscle Invasion on Outcome of Differentiated Thyroid Cancer: Systematic Review and Meta-Analysis.

Zhang L, Liu J, Wang P, et al.

Frontiers in oncology 2020; (10()):1687 doi:10.3389/fonc.2020.01687.

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival.

Krajewska J, Kukulska A, Oczko-Wojciechowska M, et al.

Frontiers in endocrinology 2020; (11()):571421 doi:10.3389/fendo.2020.571421.

Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors.

Riachy R, Ghazal N, Haidar MB, et al.

International journal of endocrinology 2020; (2020()):8649794 doi:10.1155/2020/8649794.

Multi-gene assay and clinical characteristics research in papillary thyroid carcinoma.

Deng C, Li S, Yang Z, et al.

Gland surgery 2021; (10(1)):242-251 doi:10.21037/gs-20-589.

Impact of the 8th Edition of the AJCC-TNM Staging System on Estimated Cancer-Specific Survival in Patients Aged 45-54 Years at Diagnosis with Differentiated Thyroid Carcinoma: A Single Center Report.

Maggiore R, Perticone F, Mari G, et al.

International journal of endocrinology 2021; (2021()):8820364 doi:10.1155/2021/8820364.

Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians.

Rosario PW, Côrtes MCS, Franco Mourão G

Endocrine-related cancer 2021; (28(4)):R111-R119.

Trends in incidence and histological pattern of thyroid cancer in Ho Chi Minh City, Vietnam (1996-2015): a population-based study.

Pham DX, Nguyen HD, Phung AHT, et al.

BMC cancer 2021; (21(1)):296 doi:10.1186/s12885-021-08023-z.

Thyroid Lobectomy for Low-Risk Papillary Thyroid Cancer: A National Survey of Low- and High-Volume Surgeons.

McDow AD, Saucke MC, Marka NA, et al.

Annals of surgical oncology 2021; (28(7)):3568-3575 doi:10.1245/s10434-021-09898-9.

Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis.

Kwak D, Ha J, Won Y, et al.

BMJ open 2021; (11(5)):e043007 doi:10.1136/bmjopen-2020-043007.

The effect of I-131 therapy on pregnancy outcomes after thyroidectomy in patients with differentiated thyroid carcinoma: a meta-analysis.

Zhang L, Huang Y, Zheng Y, et al.

Endocrine 2021; (73(2)):301-307 doi:10.1007/s12020-021-02657-6.

Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?

Han K, Noh HM, Jeong HM, Lim YC

Annals of surgical oncology 2021; (28(12)):7533-7544 doi:10.1245/s10434-021-10164-1.

Preoperative ultrasound characteristics in determining the likelihood of requiring completion thyroidectomy for cytologically confirmed (Bethesda VI) papillary thyroid tumors with 1 - 4 cm in diameter.

Leong D, Ng K, Nguyen H, Ryan S

Asian journal of surgery 2022; (45(1)):197-201 doi:10.1016/j.asjsur.2021.04.037.

Survival in differentiated thyroid carcinoma: Comparison between the 7th and 8th editions of the AJCC/UICC TNM staging system and the ATA initial risk stratification system.

Cavalheiro BG, de Matos LL, Leite AKN, et al.

Head & neck 2021; (43(10)):2913-2922 doi:10.1002/hed.26773.

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.

Jafri S, Yaqub A

Cureus 2021; (13(8)):e17488 doi:10.7759/cureus.17488.

BRAF mutations in thyroid cancer.

Scheffel RS, Dora JM, Maia AL

Current opinion in oncology 2022; (34(1)):9-18 doi:10.1097/CCO.0000000000000797.

Predictors of Response to Therapy Among Post Thyroidectomy Adult Filipino Patients with Papillary Thyroid Carcinoma Based on the 2015 American Thyroid Association Guidelines.

Santiago AG, Isidro MJ, Parra J

Journal of the ASEAN Federation of Endocrine Societies 2021; (36(2)):161-166 doi:10.15605/jafes.036.02.18.

Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.

Pasqual E, Schonfeld S, Morton LM, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(13)):1439-1449 doi:10.1200/JCO.21.01841.

Thyroid Cancer Incidence and Mortality Trends in the United States: 2000-2018.

Megwalu UC, Moon PK

Thyroid : official journal of the American Thyroid Association 2022; (32(5)):560-570 doi:10.1089/thy.2021.0662.

Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Baloch ZW, Asa SL, Barletta JA, et al.

Endocrine pathology 2022; (33(1)):27-63 doi:10.1007/s12022-022-09707-3.

Macroscopic extranodal extension is an independent predictor of lung metastasis in papillary thyroid cancer.

Hei H, Gong W, Zheng C, et al.

Endocrine 2022; (77(1)):73-79 doi:10.1007/s12020-022-03045-4.

Outcomes and Trends of Treatments in High-Risk Differentiated Thyroid Cancer.

Abiri A, Goshtasbi K, Torabi SJ, et al.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2023; (168(4)):745-753 doi:10.1177/01945998221095720.

Thoracic Spinal Cord Compression Secondary to Metastatic Papillary Thyroid Carcinoma: An Unusual Oncological Phenomenon.

Saad EA, Abdalla M, Awadelkarim AM, et al.

Cureus 2022; (14(4)):e24206 doi:10.7759/cureus.24206.

Concepts of Pathological Staging and Prognosis in Papillary Thyroid Carcinoma.

Lam AK

Methods in molecular biology (Clifton, N.J.) 2022; (2534()):109-119 doi:10.1007/978-1-0716-2505-7_8.

Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature review.

Kim HAJ, Nichols AC, Rachakonda R, et al.

Cancer reports (Hoboken, N.J.) 2022; (5(10)):e1654 doi:10.1002/cnr2.1654.

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Haddad RI, Bischoff L, Ball D, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(8)):925-951.

Strategies for Radioiodine Treatment: What's New.

Sparano C, Moog S, Hadoux J, et al.

Cancers 2022; (14(15)) doi:10.3390/cancers14153800.

Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction.

Lee IT, Chen W, Chen Q, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(12)):1210-1215 doi:10.1016/j.eprac.2022.08.006.

Thyroglobulin antibodies: Trend over time and clinical impact in differentiated thyroid carcinoma with and without radioiodine ablation.

Iglesias ML, Calabretta JM, Coggiola O, Califano I

Endocrinologia, diabetes y nutricion 2022; (69(9)):702-708 doi:10.1016/j.endien.2022.11.005.

Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients.

Peng X, Lei J, Li Z, Zhang K

Frontiers in oncology 2022; (12()):1099268 doi:10.3389/fonc.2022.1099268.

The effectiveness and safety of prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma patients: A meta-analysis.

Wang Y, Xiao Y, Pan Y, et al.

Frontiers in endocrinology 2022; (13()):1094012 doi:10.3389/fendo.2022.1094012.

Brain metastases of papillary thyroid carcinoma origin are derived from aggressive histologic variants and demonstrate similar adverse morphology in the metastatic lesion.

Gubbiotti MA, Livolsi V

Clinical neurology and neurosurgery 2023; (227()):107639 doi:10.1016/j.clineuro.2023.107639.

Cardiovascular Outcomes of Differentiated Thyroid Cancer Patients on Long Term TSH Suppression: A Systematic Review and Meta-Analysis.

Yu J, Kaur R, Ayeni FE, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2023; (55(6)):379-387 doi:10.1055/a-2084-3408.

The 2023 Bethesda System for Reporting Thyroid Cytopathology.

Ali SZ, Baloch ZW, Cochand-Priollet B, et al.

Thyroid : official journal of the American Thyroid Association 2023; (33(9)):1039-1044 doi:10.1089/thy.2023.0141.

Exploring temporal trends and influencing factors for thyroid cancer in Guangzhou, China: 2004-2018.

Zhou J, Liang B, Liu Y, et al.

Endocrine 2024; (84(2)):509-523 doi:10.1007/s12020-023-03578-2.

Current practice in intermediate risk differentiated thyroid cancer - a review.

do Prado Padovani R, Duarte FB, Nascimento C

Reviews in endocrine & metabolic disorders 2024; (25(1)):95-108 doi:10.1007/s11154-023-09852-y.

Thyroid Cancer: A Review.

Boucai L, Zafereo M, Cabanillas ME

JAMA 2024; (331(5)):425-435 doi:10.1001/jama.2023.26348.

Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines.

Kim MJ, Moon JH, Lee EK, et al.

Endocrinology and metabolism (Seoul, Korea) 2024; (39(1)):47-60 doi:10.3803/EnM.2024.1937.

Eye-Related Adverse Events After I-131 Radioiodine Therapy: A Systematic Review of the Current Literature.

Rahmanipour E, Askari E, Ghorbani M, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2024; (30(8)):770-778 doi:10.1016/j.eprac.2024.04.017.

Excellent RAI therapeutic response on a patient presenting skull metastasis of follicular thyroid cancer after 15 years.

Carbone A, Verrienti A, Cito DS, et al.

Endocrine 2025; (87(2)):468-473 doi:10.1007/s12020-024-04036-3.

Predictors of Bilateral Disease in Low-Risk Papillary Thyroid Cancer: Histopathologic Insights and Preoperative Ultrasonography.

Rodriguez Schaap PM, Papachristos A, Serrao-Brown H, et al.

Annals of surgical oncology 2025; (32(4)):2335-2343 doi:10.1245/s10434-024-16352-z.

Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories.

Weis H, Weindler J, Schmidt K, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025; doi:10.2967/jnumed.124.269091.

The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.

Moon S, Song YS, Jung KY, et al.

Endocrinology and metabolism (Seoul, Korea) 2025; (40(3)):357-384 doi:10.3803/EnM.2025.2465.

Clinical prognostic risk assessment of different pathological subtypes of papillary thyroid cancer: a systematic review and network meta-analysis.

Zhao J, Zhang W, Lu D, et al.

Langenbeck's archives of surgery 2025; (410(1)):251 doi:10.1007/s00423-025-03841-2.

Lobectomy Versus Total Thyroidectomy Across 2015 American Thyroid Association Low-to-Intermediate-Risk Papillary Thyroid Carcinoma.

Wong RSH, Sri Ram TM, Xia Y, et al.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2025; (173(5)):1099-1110 doi:10.1002/ohn.70009.

Total thyroidectomy versus lobectomy for unilateral papillary thyroid cancer and lateral lymph node metastasis: A systematic review and meta-analysis.

Wu S, Zhao Y, Li H, et al.

Surgery 2025; (190()):109937 doi:10.1016/j.surg.2025.109937.

Thyroid-Stimulating Hormone Suppression Therapy in Thyroid Cancer: Balancing Benefits and Harms.

Pishdad R, Ahmadi S

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):401-405 doi:10.1016/j.eprac.2025.12.002.

Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality.

Gatta E, Pirola I, Gandossi E, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):416-426 doi:10.1016/j.eprac.2025.12.003.

PROGNOSTIC IMPLICATIONS OF HOBNAIL CELL MORPHOLOGY IN PAPILLARY THYROID CARCINOMA: A CLINICOPATHOLOGICAL ANALYSIS.

Kayhan Y, Azizova L, Gündüz B, et al.

Acta endocrinologica (Bucharest, Romania : 2005) 2025; (21(1)):80-90 doi:10.4183/aeb.2025.80.

Radioactive iodine effects on ovarian reserve: a systematic review and metaanalysis.

Bukhari SQ, Mirghani H

Frontiers in endocrinology 2026; (17()):1636824 doi:10.3389/fendo.2026.1636824.

Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.

Bondet de La Bernardie S, Bernier MO, Buffet C, et al.

European thyroid journal 2026; (15(3)).

A nomogram predicting dysphagia risk after adjuvant iodine-131 therapy in patients with papillary thyroid carcinoma.

Jiang H, Chen J, Zhu H, Li Z

Nuclear medicine communications 2026; (47(9)):1021-1028 doi:10.1097/MNM.0000000000002171.

Vertebral fracture risk in patients with differentiated thyroid cancer receiving TSH-suppressive therapy.

Gogas Yavuz D, Dincer Yazan C, Hekimsoy Z, et al.

Endocrine connections 2026; (15(7)) doi:10.1530/EC-26-0103.